Alamar Biosciences earnings release, May 8, 2026

Alamar Biosciences, Inc. (ALMR) · Form 8-K, Item 2.02 · Filed · SEC filing

Alamar Biosciences Reports First Quarter 2026 Financial Results

FREMONT, Calif.--(GLOBE NEWSWIRE)—Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026.

Recent Highlights

• Generated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025.

• Launched two new products, NULISAseq™ Neuro 220 Panel and NULISAqpcr™ AD 5-plex Assay, furthering our leadership in neurodegenerative disease research.

• Raised approximately $220 million in gross proceeds from our initial public offering in April 2026.

"We began 2026 with a record quarter, nearly doubling revenue year over year as our NULISA platform gained rapid global traction among leading academic research and biopharma customers," said Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences. "With our balance sheet significantly strengthened by the proceeds of our recent IPO, we are well-positioned to accelerate adoption of our Precision Proteomics platform and establish a new gold standard in protein detection and analysis."

First Quarter 2026 Financial Results

Revenue was $26.0 million for the first quarter of 2026, a 99% increase from $13.1 million for the corresponding prior-year period. Instrument revenue grew 78% to $7.4 million, from $4.1 million for the corresponding prior-year period, driven primarily by an increase in instrument placements. Consumable revenue grew 178% to $14.0 million, from $5.0 million for the corresponding prior-year period, driven primarily by pull-through tied to the larger instrument installed base as well as by a slight increase in the average selling price of our consumables. Services and other revenue grew 20% to $4.7 million, from $3.9 million for the corresponding prior-year period.

Gross margin was 56% for the first quarter of 2026, as compared to 49% for the corresponding prior-year period. The increase in gross margin was primarily driven by manufacturing efficiencies realized through larger consumables production volumes, higher average selling prices across both instruments and consumables, and by a favorable shift in product mix toward higher-margin consumables.

Operating expenses were $26.8 million for the first quarter of 2026, a 79% increase from $14.9 million for the corresponding prior-year period. The year-over-year increase in operating expenses was primarily related to increased personnel costs, increased costs related to expansion of our product offerings, and increased professional costs for legal and accounting services.

Operating loss was $12.3 million for the first quarter of 2026, as compared to an operating loss of $8.6 million for the corresponding prior-year period. This includes $1.5 million of stock-based compensation for the first quarter of 2026, as compared to $0.6 million for the first quarter of 2025.

Net loss was $21.3 million for the first quarter of 2026, including a loss of $8.6 million related to the remeasurement of convertible notes, and higher than the $7.7 million net loss in the corresponding prior-year period.

Cash, cash equivalents, and restricted cash were $69.5 million as of March 31, 2026.

Recent Developments

In April, after quarter end, Alamar Biosciences completed its initial public offering, raising $197.8 million of net proceeds, after deducting underwriter commissions, discounts and other expenses incurred by the company.

The company intends to provide full-year 2026 revenue guidance in conjunction with its second quarter 2026 earnings release in August 2026.

About Alamar Biosciences, Inc.

Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended March 31, — (Unaudited, in thousands, except share and per share data)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenue:Product revenue21,3419,169
Revenue:Service and other revenue4,6943,922
Revenue:Total revenue(1)26,03513,091
Cost of revenue:Cost of product revenue(2)9,8105,371
Cost of revenue:Cost of service and other revenue(2)1,7681,331
Cost of revenue:Total cost of revenue11,5786,702
Cost of revenue:Gross profit14,4576,389
Operating expenses:Research and development(2)13,0178,302
Operating expenses:Selling, general and administrative(2)13,7876,640
Operating expenses:Total operating expenses26,80414,942
Operating expenses:Loss from operations-12,347-8,553
Operating expenses:Interest income, net539786
Operating expenses:Interest expense-223-46
Operating expenses:Loss on remeasurement of convertible notes-8,594
Operating expenses:Other (expense) income, net-236154
Operating expenses:Net loss before income tax-20,861-7,659
Operating expenses:Provision for income taxes464
Operating expenses:Net loss-21,325-7,659
Operating expenses:Net loss per share, basic and diluted-1.74-0.68
Operating expenses:Weighted-average common shares outstanding, basic and diluted12,259,81111,258,870

Income Statement

Three Months Ended March 31, — Includes stock-based compensation expense as follows: (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Cost of product revenue148
Cost of service and other revenue2213
Research and development392229
Selling, general and administrative1,039369
Total stock-based compensation expense1,467619

Balance Sheet

March 31, 2026 — (Unaudited, in thousands)

March 31, 2026December 31, 2025
Current AssetsCash and cash equivalents64,58630,002
Current AssetsAccounts receivable19,52412,753
Current AssetsInventory39,93138,482
Current AssetsPrepaid expenses and other current assets17,43213,468
Current AssetsTotal current assets141,47394,705
Current AssetsRestricted cash4,9074,907
Current AssetsProperty and equipment, net10,47210,498
Current AssetsOperating lease right-of-use assets25,67126,130
Current AssetsCapitalized software, net1,8361,988
Current AssetsOther assets—noncurrent2,0921,764
Current AssetsTotal assets186,451139,992
Current LiabilitiesAccounts payable5,6355,872
Current LiabilitiesAccrued and other current liabilities16,81415,759
Current LiabilitiesShort-term operating lease liabilities1,5992,099
Current LiabilitiesTotal current liabilities24,04823,730
Current LiabilitiesLong-term operating lease liabilities28,97929,564
Current LiabilitiesWarrant liabilities331247
Current LiabilitiesTerm debt9,8779,810
Current LiabilitiesConvertible note65,094
Current LiabilitiesOther noncurrent liabilities1,197599
Current LiabilitiesTotal liabilities129,52663,950
Current LiabilitiesConvertible preferred stock234,996234,996
Stockholders’ deficitCommon stock11
Stockholders’ deficitAdditional paid-in capital12,1089,892
Stockholders’ deficitAccumulated other comprehensive loss-80-72
Stockholders’ deficitAccumulated deficit-190,100-168,775
Stockholders’ deficitTotal stockholders’ deficit-178,071-158,954
Stockholders’ deficitTotal liabilities, convertible preferred stock and stockholders' deficit186,451139,992
Full release

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar Biosciences’ future plans and prospects, its ability to accelerate adoption of its platform... (truncated)s and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property and other risks and uncertainties described in Alamar Biosciences’ filings with the Securities and Exchange Commission (SEC), including those described from time to time under the caption “Risk Factors” and elsewhere in Alamar Biosciences’ filings with the SEC, including its prospectus filed with the SEC pursuant to Rule 424(b)(4), dated April 16, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Investor contact: investors@alamarbio.com

Media contact: media@alamarbio.com

Alamar Biosciences, Inc.

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except share and per share data)

(1)

The following table represents revenue by source for the periods indicated:

(2)

Includes stock-based compensation expense as follows:

Alamar Biosciences, Inc.

Condensed Consolidated Balance Sheets

(Unaudited, in thousands)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Alamar Biosciences earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.